Staidson Beijing Biopharma (SHE:300204) — Market Cap & Net Worth
Market Cap & Net Worth: Staidson Beijing Biopharma (300204)
Staidson Beijing Biopharma (SHE:300204) has a market capitalization of $1.57 Billion (CN¥10.75 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #7096 globally and #1513 in its home market, demonstrating a -1.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Staidson Beijing Biopharma's stock price CN¥19.85 by its total outstanding shares 541344345 (541.34 Million). Also see Staidson Beijing Biopharma balance sheet assets for a full breakdown of the balance sheet.
Staidson Beijing Biopharma Market Cap History: 2015 to 2026
Staidson Beijing Biopharma's market capitalization history from 2015 to 2026. Data shows change from $1.84 Billion to $1.57 Billion (-0.68% CAGR). Also see 300204 cash generation efficiency for how efficiently the company converts equity into cash flow.
Staidson Beijing Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Staidson Beijing Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Staidson Beijing Biopharma share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
9.83x
Staidson Beijing Biopharma's market cap is 9.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.30 Billion | $1.40 Billion | $257.27 Million | 0.93x | 5.06x |
| 2017 | $1.02 Billion | $1.39 Billion | $263.03 Million | 0.74x | 3.89x |
| 2018 | $838.98 Million | $806.08 Million | $134.06 Million | 1.04x | 6.26x |
| 2019 | $880.88 Million | $661.49 Million | $27.30 Million | 1.33x | 32.27x |
| 2020 | $715.32 Million | $425.21 Million | -$133.02 Million | 1.68x | N/A |
| 2021 | $1.39 Billion | $584.29 Million | -$137.40 Million | 2.38x | N/A |
| 2022 | $1.08 Billion | $548.99 Million | -$197.01 Million | 1.96x | N/A |
| 2023 | $804.83 Million | $364.18 Million | -$398.89 Million | 2.21x | N/A |
| 2024 | $586.99 Million | $324.82 Million | -$144.84 Million | 1.81x | N/A |
| 2025 | $2.16 Billion | $220.23 Million | -$77.76 Million | 9.83x | N/A |
Competitor Companies of 300204 by Market Capitalization
Companies near Staidson Beijing Biopharma in the global market cap rankings as of September 19, 2026. Review Staidson Beijing Biopharma (300204) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Staidson Beijing Biopharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Staidson Beijing Biopharma Historical Marketcap From 2015 to 2026
Between 2015 and today, Staidson Beijing Biopharma's market cap moved from $1.84 Billion to $ 1.57 Billion, with a yearly change of -0.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.57 Billion | -27.34% |
| 2025 | CN¥2.16 Billion | +268.69% |
| 2024 | CN¥586.99 Million | -27.07% |
| 2023 | CN¥804.83 Million | -25.29% |
| 2022 | CN¥1.08 Billion | -22.51% |
| 2021 | CN¥1.39 Billion | +94.35% |
| 2020 | CN¥715.32 Million | -18.79% |
| 2019 | CN¥880.88 Million | +4.99% |
| 2018 | CN¥838.98 Million | -18.05% |
| 2017 | CN¥1.02 Billion | -21.39% |
| 2016 | CN¥1.30 Billion | -29.19% |
| 2015 | CN¥1.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Staidson Beijing Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.57 Billion USD |
| MoneyControl | $1.57 Billion USD |
| MarketWatch | $1.57 Billion USD |
| marketcap.company | $1.57 Billion USD |
| Reuters | $1.57 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respi… Read more